文献速递肝胆胰外科围术期管理与 ERAS

腹腔镜与开腹胰十二指肠切除术治疗胰腺导管腺癌的肿瘤学结局与长期生存比较

Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival.
PubMed 文献 · Surg Endosc · 2019-07-17

该研究系统检索截至2018年12月25日发表的文献,纳入6项比较性队列研究,比较腹腔镜胰十二指肠切除术(LPD)与开腹胰十二指肠切除术(OPD)治疗胰腺导管腺癌(PDAC)的肿瘤学结局和长期生存。结果显示两组在淋巴结清扫数、R0切除率、阳性淋巴结数、辅助治疗率及辅助治疗时间方面无显著差异,LPD组3年、4年、5年生存率显著优于OPD组。

要点

  • LPD与OPD在淋巴结清扫数、R0切除率、阳性淋巴结数上无显著差异。
  • LPD组3年、4年、5年生存率显著优于OPD组。
  • 两组辅助治疗率及辅助治疗时间无显著差异。

核心结论

  • 对于PDAC,LPD的肿瘤学结局与OPD相当,且在术后长期生存方面似乎更有前景。

研究设计与样本

  • 系统检索截至2018年12月25日发表的LPD治疗PDAC的研究,最终纳入6项比较性队列研究。

主要发现

  • LPD与OPD在淋巴结清扫数(OR 1.96,95%CI -1.17至5.09,p=0.22)、R0切除率(OR 1.44,95%CI 1.00至2.06,p=0.05)、阳性淋巴结数(OR -0.44,95%CI -1.06至0.17,p=0.16)、辅助治疗率(OR 1.04,95%CI 0.68至1.59,p=0.86)及辅助治疗时间(OR -6.21,95%CI -16.00至3.59,p=0.21)方面均无显著差异。
  • LPD的1年生存(OR 1.20,95%CI 0.87至1.65,p=0.28)和2年生存(OR 1.25,95%CI 0.94至1.66,p=0.13)与OPD相似。
  • LPD组3年生存(OR 1.50,95%CI 1.12至2.02,p=0.007)、4年生存(OR 1.73,95%CI 1.02至2.93,p=0.04)和5年生存(OR 2.11,95%CI 1.35至3.31,p=0.001)显著更长。

临床怎么用

  • 在具备技术条件的中心,LPD可作为PDAC患者胰十二指肠切除术的可行选择,肿瘤学结局与OPD相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study aimed to compare the oncologic outcomes and long-term survival of laparoscopic pancreaticoduodenectomy (LPD) and open pancreaticoduodenectomy (OPD) for patients diagnosed with pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Substantial evidence demonstrated that LPD is technically safe and feasible with perioperative outcomes equivalent to that of OPD. However, for patients with malignancy, especially PDAC, the oncologic outcomes and long-term survival of patients who underwent LPD remains to be elucidated. METHODS: Studies on LPD for the treatment of PDAC published before December 25, 2018 were searched online. The oncologic outcomes (e.g., numbers of lymph nodes retrieved, negative margin (R0) resection), and long-term survival (postoperative survival from 1 to 5 year) of LPD were compared to that of ODP. RESULTS: After screening 1507 studies, six comparative cohort studies, which reported the oncologic outcomes and long-term survival of patients with PDAC were included. No significant difference was found between LPD and OPD regarding lymph nodes harvested (OR 1.96, 95% CI - 1.17 to 5.09, p = 0.22), R0 rate (OR 1.44, 95% CI 1.00 to 2.06, p = 0.05), number of positive lymph nodes (OR - 0.44, 95% CI - 1.06 to 0.17, p = 0.16), rate of adjuvant treatment (OR 1.04, 95% CI 0.68 to 1.59, p = 0.86) and time to adjuvant treatment (OR - 6.21, 95% CI - 16.00 to 3.59, p = 0.21). LPD showed similar 1-year (OR 1.20, 95% CI 0.87 to 1.65, p = 0.28), and 2-year survival (OR 1.25, 95% CI 0.94 to 1.66, p = 0.13) to that of OPD. The 3-year (OR 1.50, 95% CI 1.12 to 2.02, p = 0.007), 4-year (OR 1.73, 95% CI 1.02 to 2.93, p = 0.04), and 5-year survival (OR 2.11, 95% CI 1.35 to 3.31, p = 0.001) were significantly longer in LPD group. CONCLUSION: For the treatment of PDAC, the oncologic outcomes of LPD were equivalent to that of OPD; LPD seemed promising regarding the postoperative long-term survival.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Chen K, Zhou Y, Jin W, et al. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. Surg Endosc. 2019. PMID: 31317331. doi:10.1007/s00464-019-06968-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。